Publications by authors named "Richard Heng"

8Publications

N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity.

Authors:
Achim Schlapbach Laszlo Revesz Carole Pissot Soldermann Thomas Zoller Catherine H Régnier Frédéric Bornancin Thomas Radimerski Jutta Blank Ansgar Schuffenhauer Martin Renatus Paulus Erbel Samu Melkko Richard Heng Oliver Simic Ralf Endres Markus Wartmann Jean Quancard

Bioorg Med Chem Lett 2018 07 9;28(12):2153-2158. Epub 2018 May 9.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2018

Modulating ADME Properties by Fluorination: MK2 Inhibitors with Improved Oral Exposure.

Authors:
Juraj Velcicky Achim Schlapbach Richard Heng Laszlo Revesz Daniel Pflieger Ernst Blum Stuart Hawtin Christine Huppertz Roland Feifel Rene Hersperger

ACS Med Chem Lett 2018 Apr 20;9(4):392-396. Epub 2018 Mar 20.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
April 2018

In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I.

Authors:
Laszlo Revesz Achim Schlapbach Reiner Aichholz Roland Feifel Stuart Hawtin Richard Heng Peter Hiestand Wolfgang Jahnke Guido Koch Markus Kroemer Henrik Möbitz Clemens Scheufler Juraj Velcicky Christine Huppertz

Bioorg Med Chem Lett 2010 Aug 13;20(15):4715-8. Epub 2010 Apr 13.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
August 2010

Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy.

Authors:
Juraj Velcicky Roland Feifel Stuart Hawtin Richard Heng Christine Huppertz Guido Koch Markus Kroemer Henrik Moebitz Laszlo Revesz Clemens Scheufler Achim Schlapbach

Bioorg Med Chem Lett 2010 Feb 3;20(3):1293-7. Epub 2009 Nov 3.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
February 2010

Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.

Authors:
Achim Schlapbach Roland Feifel Stuart Hawtin Richard Heng Guido Koch Henrik Moebitz Laszlo Revesz Clemens Scheufler Juraj Velcicky Rudolf Waelchli Christine Huppertz

Bioorg Med Chem Lett 2008 Dec 11;18(23):6142-6. Epub 2008 Oct 11.

Novartis Institutes for BioMedical Research, global Discovery Chemistry, WSJ-88.508, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
December 2008

Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.

Authors:
Laszlo Revesz Birgit Bollbuck Thomas Buhl Joerg Eder Ronald Esser Roland Feifel Richard Heng Peter Hiestand Benedicte Jachez-Demange Pius Loetscher Helmut Sparrer Achim Schlapbach Rudolf Waelchli

Bioorg Med Chem Lett 2005 Dec 28;15(23):5160-4. Epub 2005 Sep 28.

Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Autoimmunity and Transplantation, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
December 2005

New highly potent and selective adenosine A(3) receptor antagonists.

Authors:
Neil J Press Thomas H Keller Pamela Tranter David Beer Ken Jones Alexander Faessler Richard Heng Christine Lewis Trevor Howe Peter Gedeck Lazzaro Mazzoni John R Fozard

Curr Top Med Chem 2004 ;4(8):863-70

Respiratory Disease Area, Novartis Horsham Research Center, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, UK.

View Article and Find Full Text PDF
October 2004

A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinone p38 kinase inhibitors.

Authors:
Achim Schlapbach Richard Heng Franco Di Padova

Bioorg Med Chem Lett 2004 Jan;14(2):357-60

Novartis Institute for Biomedical Research, Arthritis and Bone Metabolism, Lichtstrasse, CH-4002, Basel, Switzerland.

View Article and Find Full Text PDF
January 2004